Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Shanghai Green Valley

Celgene building

Celgene bulks up pipeline again with $2.1bn Prothena deal

Acquires candidates with potential in Alzheimer’s, ALS and dementia

- PMLiVE

Boehringer abandons PDE-targeted Alzheimer’s drug

But will keep testing the candidate in schizophrenia

- PMLiVE

A catalyst for change

China’s plan to boost innovation and improve drug accessibility

- PMLiVE

Takeda and Zinfandel abandon Alzheimer’s drug

Pioglitazone failed to show therapeutic improvements in late-stage testing

AstraZeneca AZ

AZ pushes harder into China with new joint venture

The Anglo-Swedish group creates a new pharmaceutical business with the Chinese FIIF

Ageing Asia: What does this mean for the future of healthcare?

Over the last 30 years, Asia’s economic growth has resulted in improved education and healthcare across a broad base of the population. This has contributed to declining fertility and increasing...

Research Partnership

- PMLiVE

Axovant joins ever-growing Alzheimer’s failure club

5-HT6 inhibitor Intepirdine followsin the footsteps of Lundbeck's idalopirdine

Biogen Idec building

Biogen says trial extension data keep Alzheimer’s drug on track

Releases updated results from the PRIME trial of anti-amyloid drug aducanumab

- PMLiVE

Alzheon says data backs potential of Alzheimer’s candidate

US biotech points to new analysis of phase III results for tramiprosate

- PMLiVE

Woodford investment pushes Dementia Discovery Fund to £100m

Fund aims to back 40 projects over its 15-year term

Online therapy for dementia carers to be studied

UK researchers will assess computerised Cognitive Behaviour Therapy

- PMLiVE

AZ gets rapid approval in China for Tagrisso

Lung cancer treatment becomes first medicine to pass through the country's Priority Review pathway

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links